Synsorb Biotech / SYBB - One of Canada`s Top 10 Life Sciences - 500 Beiträge pro Seite

[Montezuma]

http://www.canadastopten.com/

CANADA`S TOP 10 LIFE SCIENCES CORPORATE
FINANCING/PARTNERING PROSPECTS COMPETITION
DECEMBER 4, 2000 - OTTAWA CONGRESS CENTRE

This Year`s Winners:

Active Pass Pharmaceuticals Inc. (Vancouver BC)
Inflazyme Pharmaceuticals Ltd. (Richmond BC)
Adherex Technologies Inc. (Ottawa ON)
IMI International Medical Innovations Inc. (Toronto ON)
Bioniche Life Sciences Inc.(Belleville ON)
Kinetek Pharmaceuticals Inc. (Vancouver BC)
ConjuChem Inc.(Montreal PQ)
ProMetic Life Sciences (Montreal PQ)
Cytovax Biotechnologies Inc.(Edmonton AB)
SYNSORB Biotech Inc. (Calgary AB)

Canada`s Top 10 Life Sciences Corporate
Finanancing/Partnering Prospects competition
is held in conjunction with the 7th Annual Ottawa
Life Sciences National Conference and Exhibition (December 4-6, 2000),
"The BioProducts Revolution" 1:30 - 5:30 PM - Monday, December 4th, 2000
Ottawa Congress Centre Ottawa, Ontario, Canada

Canada`s Top 10 Life Sciences
Corporate Investment/Partnering Prospects

December 4th, 2000
1:30-5:30 p.m.
Ottawa Congress Centre
Ottawa, Canada

Canada has become a hotbed of emerging life sciences companies and now
ranks second only to the United States in terms of the number of biotechnology
companies, the number of employees and annual revenues. Fueled by leading
edge research and development, a strong pipeline, strategic alliances and a
growing capital base, a new generation of Canadian companies is taking the
stage.

"Canada`s Top 10 Life Sciences Corporate Investment/Partner Prospects" is an
investment and partnering forum held in conjunction with the 7th Annual Ottawa
Life Sciences National Conference and Exhibition - Canada`s Premier Life
Sciences Conference. Conference delegates, investors and potential alliance
partners will have a unique opportunity to see the very best opportunities as
determined by a jury of experts.

The forum is focused on growth oriented biotechnology, biomedical, health and
advanced agricultural technology companies who are looking for new strategic
partnerships and investments of between $2 million and $20 million. Companies
selected for the Top 10 Session will be asked to make a 15 minute presentation
on their opportunity. A pre-conference reception follows the session (sponsored
by TBD).

THIS YEAR`S WINNERS:

Active Pass Pharmaceuticals Inc. (Vancouver BC)
Adherex Technologies Inc. (Ottawa ON)
Bioniche Life Sciences Inc. (Belleville ON)
ConjuChem Inc. (Montreal PQ)
Cytovax Biotechnologies Inc. (Edmonton AB)
Inflazyme Pharmaceuticals Inc.(Richmond BC)
IMI International Medical Innovations Inc. (Toronto ON)
Kinetek Pharmaceuticals (Vancouver BC)
ProMetic Life Sciences (Montreal PQ)
SYNSORB Biotech Inc. (Calgary AB)

Click here to view the Conference Program

To attend Top Ten and Conference Sessions - Deadline for registration is
November 29, 2000 (early bird special rate registration is October 31)

Sponsored by: Borden Ladner Gervais LLP

[Montezuma]

Zwei weitere Termine:

December 6-8

SYNSORB attending conference "Infection Control: Advances in Control of Nosocomical Infection - 2000" in Madison WI


December 14-19

Dr R.M. Ratcliffe presenting a talk on "Process and Pharmaceutical Development of Carbohydrate Therapeutics" at the "2000 Chemical Congress of Pacific Basin Societies (Pacifichem 2000)" in Honolulu, HI

[Shareholdersnightmare]

Ein Unternehmen mit 2 sehr aussichtsreichen Medikamenten in Phase III (siehe auch Thread: SYNSORB Biotech Q3/Q4 2000 !!!). Es scheinen sich immer mehr Investoren dafür zu interessieren. Ich denke wir haben mittlerweile den Weg nach Norden wiedergefunden und bin zuversichtlich für die nächsten Wochen, Monate und Jahre.

Danke auch an Montezuma, der hier nochmal die wichtigsten Termine dieser Tage gepostet hat.

Ich denke es wird auch bald (bis Ende des Jahres?!?) ein Update zum Pk-Programm geben, wobei die Gerüchte darum dem Wert auch kurzfristig schon jetzt scheinbar wieder etwas Kursfantasie verleihen (nachdem diese in letzter Zeit ja wohl vollkommen abhanden gekommen war, bzw. in der allgemeinen Panik sich eher ins negative umgekehrt hatten).

Wenn sich die gesamtbörsliche Lage sich jetzt langsam wieder stabilisieren sollte, ist wohl auch die Zeit der Margin Calls (Nachschußaufforderungen) und des Tax Selling (Verkauf aus steuerlichen Gründen) vorbei und wir blicken wieder in eine rosigere Zukunft, was den Kursverlauf anbetrifft.


Stay long and strong


Keine Kauf-/Verkaufsempfehlung. Reflektiert lediglich meine persönliche Meinung.

[gholzbauer]

Dazu möchte ich anmerken: kauft Synsorb, was das Zeug hält, bzw. was das Konto hergibt!

Das ist natürlich keine Kaufempfehlung.

[Shareholdersnightmare]

gholzbauer Du Schelm!

Du kannst wohl meine Gedanken lesen...

[Shareholdersnightmare]

gholzbauer, Du bist doch nicht etwa der Typ von

http://www.chartanalysen-trading.de/?

Der ist auch gerade erst mit seiner Analyse fertiggeworden...


Stay long and strong!

[gholzbauer]

Nö.

[Shareholdersnightmare]

[Montezuma]

Bin mal gespannt, ob sich da jemand für Synsorb interessiert. Wenn nicht, dann sollte man wohl besser seine Bestände abbauen.

February 6-8

SYNSORB in Toronto meeting with Potential Investors

[Shareholdersnightmare]

@Montezuma

Jeder muß eben tun, was er tun muß (und nicht lassen kann)!

Good luck to you anyways, pal!

[Montezuma]

Übermorgen wieder mal was im Fernsehen:
Vielleicht hilfts!

February 8

David Cox to be interviewed on ROB TV for Biotech segment

[Montezuma]

Wednesday June 6, 4:43 pm Eastern Time
Press Release
SYNSORB Receives Milestone Payment of BCY Shares
CALGARY, Alberta--(BUSINESS WIRE)--June 6, 2001--SYNSORB Biotech Inc. (``SYNSORB``) (NASDAQ:SYBB - news; TSE:SYB. - news), today announced that pursuant to an Assignment Agreement with BCY LifeSciences Inc. (``BCY``) (CDNX: BCY - news), SYNSORB has been granted an additional 200,000 common shares of that company, bringing SYNSORB`s total ownership in BCY to 1,300,000 or 11.5% of the issued and outstanding shares.

``The achievement of this first milestone clearly demonstrates BCY`s continued progress,`` stated Dr. David Cox, SYNSORB`s President and CEO. ``I am pleased that SYNSORB can remain focused on successful development of SYNSORB Cd® while retaining access to any future potential upside from our ownership in spin-off companies such as BCY.``

This first milestone payment of 200,000 shares was triggered by BCY successfully completing the fractionation of a low molecular weight dextran and the bio-assay of these fractions.

An additional 600,000 common shares will be issued to SYNSORB upon the completion of other pre-determined milestones.

Under the Assignment Agreement and a Consulting Agreement signed with BCY in March of 2000, SYNSORB received 1,100,000 common shares of BCY. SYNSORB assigned to BCY its license of certain technologies relating to the treatment of lung complications such as Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD), and agreed to act as a resource to BCY in the development of those assigned technologies

[Montezuma]

Heute scheint SYBB wieder durchzustarten:

Aktuell +20 Prozent! Gründe? mmmmhhh....